Tenapanor interactions
Tenapanor (Ibsrela, Xphozah) has 4 documented interactions across the FDA labels and fact sheets we index: 0 major, 4 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.
Interactions from the label
Moderate interactions (4)
OATP2B1 Substrates: Potential for reduced exposure of the concomitant drug (e.g., enalapril). (Tenapanor label, Drug interactions)
OATP2B1 Substrates: Potential for reduced exposure of the concomitant drug (e.g., enalapril). (Tenapanor label, Drug interactions)
When enalapril was coadministered with XPHOZAH (30 mg twice daily for five days), the peak exposure (C max ) of enalapril and its active metabolite, enalaprilat, decreased by approximately 70% and total systemic exposures (AUC) decreased by 50 to 65% compared to when enalapril was administered alone [see Clinical Pharmacology (12.3) ] . (Tenapanor label, Drug interactions)
Sodium Polystyrene Sulfonate (SPS): Separate administration by at least three hours ( 7.2 ). (Tenapanor label, Drug interactions)
Check Tenapanor against everything you take. Add your full list; every pair is checked at once.
Open in the checkerNot medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.